Related Experiment Videos
Oncogenic studies with felbamate (2-phenyl-1,3-propanediol dicarbamate)
J H McGee1, W H Butler, D J Erikson
1Wallace Laboratories, Cranbury, New Jersey 08512, USA.
Abstract:
Felbamate, 2-phenyl-1,3-propanediol dicarbamate, is a novel anticonvulsant that is effective against both chemically and electrically induced seizures in laboratory animals. Oncogenic studies were conducted in mice and rats to establish a preclinical safety profile for this drug. There was an increased incidence of hepatic cell adenoma in male and female mice and in female rats. There was an increased incidence of interstitial cell tumors of the testes in the male rat.
Insights
Felbamate, an anticonvulsant, showed increased tumor incidence in preclinical oncogenic studies. Liver tumors occurred in mice and female rats, while testicular tumors appeared in male rats.
Area of Science:
- Pharmacology and Toxicology
- Oncology
- Preclinical Drug Safety
Background:
- Felbamate (2-phenyl-1,3-propanediol dicarbamate) is a novel anticonvulsant agent.
- Its efficacy has been demonstrated in animal models for chemically and electrically induced seizures.
Purpose of the Study:
- To evaluate the preclinical safety profile of Felbamate.
- To assess the oncogenic potential of Felbamate in rodent models.
Main Methods:
- Oncogenic studies were conducted in mice and rats.
- Animals were administered Felbamate to observe for tumor development.
Main Results:
- An increased incidence of hepatic cell adenoma was observed in male and female mice.
- Female rats also showed an increased incidence of hepatic cell adenoma.
- Male rats exhibited an increased incidence of interstitial cell tumors of the testes.
Conclusions:
- Felbamate demonstrated oncogenic potential in preclinical rodent studies.
- Findings indicate a need for careful consideration of risks associated with Felbamate treatment.
- Further investigation into the mechanisms of Felbamate-induced tumorigenesis may be warranted.